Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

ClinicalTrials.gov ID: NCT06880770

Public ClinicalTrials.gov record NCT06880770. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.

Study identification

NCT ID: NCT06880770
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Enrollment: 288 participants

Conditions and interventions

Conditions

Severe Hypertriglyceridemia

Interventions

Plozasiran Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 23, 2025
Primary completion: Feb 28, 2029
Completion: May 31, 2029
Last update posted: Sep 1, 2026

2025 – 2029

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90027	Recruiting
Clinical Research Site 4	Santa Clarita	California	91321	Recruiting
Research Site	New Haven	Connecticut	06519	Recruiting
Clinical Research Site 6	Springfield	Illinois	62702	Recruiting
Research Site	Indianapolis	Indiana	46202	Recruiting
Research Site	Kansas City	Kansas	66160	Recruiting
Research Site	Ann Arbor	Michigan	48109	Recruiting
Research Site	St Louis	Missouri	63110	Recruiting
Clinical Research Site 5	North Platte	Nebraska	69101	Recruiting
Research Site	New York	New York	10029	Recruiting
Clinical Research Site 3	Greensboro	North Carolina	27401	Recruiting
Research Site	Wilmington	North Carolina	28412	Recruiting
Clinical Research Site 7	Philadelphia	Pennsylvania	19107	Recruiting
Research Site	Pittsburgh	Pennsylvania	15213	Recruiting
Clinical Research Site 1	Mesquite	Texas	75149	Recruiting
Clinical Research Site 2	San Antonio	Texas	78233	Recruiting
Research Site	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06880770, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06880770 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →